Medtronic completes Diabetes IPO, flags $250M tariff hit and Medical Surgical impairment risk

Filed June 18, 2026 · Period ending April 24, 2026 · Compared to 10-K Jun 20, 2025 · ~2 min read

Key Changes

• high

  MiniMed IPO completed March 2026 (10% sold, 90% retained); post-IPO stock decline triggers goodwill impairment warning that could materially affect financials if fair value drops further.

  MD&A: MiniMed IPO and goodwill impairment risk verify on EDGAR →
• high

  Medical Surgical goodwill cushion compressed to 12% (from 20%+ prior year) on $20B allocation; no impairment recorded but margin narrowed materially.

  MD&A: Medical Surgical goodwill impairment margin verify on EDGAR →
• high

  FY2027 tariff impact estimated at $250M pre-tax (down from $200-350M FY2026 estimate); Supreme Court ruled tariffs unconstitutional, CBP refund portal launched April 2026, but refunds excluded from estimate.

  MD&A: tariff impact and Supreme Court ruling verify on EDGAR →